The Biotech Intelligence Brief

This week on The Biotech Intelligence Brief , we examine one of the most important questions in life sciences: can AI move fast enough to transform drug development while still producing evidence that regulators, clinicians, investors, and patients can trust? We deep dive into FDA RTCT, Anthropic’s Claude Science and what it signals about the next stage of scientific AI. For the last several years...

The playbook for bringing new drugs to market was just rewritten. In this episode, we break down the massive $2.1 billion valuation sweeping the AI drug discovery sector. We dive deep into the FDA’s major guidance update from last week, which outlines a historic shift toward Real-Time Clinical Trials (RTCT) —allowing regulators to stream trial data live from the cloud. Plus, we explore why global...

This week, GSK's $10.6B acquisition of Nuvalent set the new ceiling for late-cycle oncology M&A, J&J locked up a degrader antibody conjugate platform for $1B, the FDA accepted Roche's sub-Q bispecific + ADC combination for relapsed B-cell lymphoma, and BIO 2026 opened in San Diego with the conversation finally shifting from "AI is interesting" to "AI is operating.&qu...

Biotech M&A - A Quarter Trillion dollar bet and 6.8B Proteins released by ESM.

Fully Autonomous AI Biotech is Here! This is not Sci-fi anymore. This Podcast serves as a strategic intelligence report detailing how fundamentally the biotechnology industry is being restructured. We bring to your attention a historic shift from experimental pilots to integrated AI infrastructure, evidenced by massive capital infusions into platform leaders and a landmark demonstration of an AI s...

This week's pharma AI operating system is in focus, where we discuss Billions in M&A, Investments with AI in Biotech, with Credible pivotal regulatory intelligence read through. Eli Lilly signed a $2.25B pact with Profluent for AI-designed gene editors Bristol Myers Squibb deployed Anthropic's Claude across 30,000 employees, and OpenAI launched GPT-Rosalind with Novo Nordisk, Moderna,...

Ten Billion dollar M&A - Big Pharma betting on AI Designed Drugs that challenge Nature's evolution. This podcast analyzes how  agentic AI is becoming the fundamental operating layer  for the modern biotech industry. It outlines a structural shift toward the  "Three-Stack Era,"  where major drug developers are consolidating their research and infrastructure around foundation model...

This intelligence brief explores how agentic AI is transitioning from experimental discovery to large-scale operational deployment within the pharmaceutical industry. Highlighting latest trends in Biotech M&A, download covering the latest developments in AI and biotechnology, designed for pharma, biotech, and life sciences executives navigating the future of drug development, this Podcast aims...